EL7.AI
StocksMedium•25 March 2026•
1 min read

Nanobiotix Responds to Market Speculation Regarding Potential Takeover

Key Facts

1Nanobiotix issued an official statement responding to recent media speculation regarding potential intentions for a public take-over of the company.
2The company is listed on Euronext Paris (NANO) and NASDAQ (NBTX).
3Nanobiotix is a late-clinical stage biotechnology company focusing on nanotherapeutic approaches for cancer patients.

Nanobiotix, a late-clinical stage biotechnology company, has issued a formal statement addressing recent media reports regarding a potential public takeover of the company. The firm, which is dual-listed on Euronext Paris (NANO) and NASDAQ (NBTX), aims to clarify its position following a surge in market speculation. Nanobiotix specializes in developing innovative nanotherapeutic approaches specifically designed for cancer patients. While the official statement acknowledges the existence of these rumors, it does not confirm any definitive acquisition deal or formal bid at this stage. Such speculation typically triggers significant price volatility within the biotech sector as investors weigh the probability of a formal takeover. Market participants are now closely monitoring the situation for further developments or official regulatory filings from the company.